Oxford Biomedica Solutions
Kayla Friscia is an experienced scientist specializing in downstream process development within the biotechnology field. Currently serving as Scientist I at Oxford Biomedica Solutions since March 2022, Kayla has previously held roles at Homology Medicines, Inc., Codiak BioSciences, and Momenta Pharmaceuticals, with a progression from Associate Process Engineer to Senior Research Associate II. Kayla's educational background includes a Bachelor of Science degree in Biology and Biotechnology, Biochemistry from Worcester Polytechnic Institute, and completion of a short course in Downstream Processing from MIT Professional Education. Additional experiences include instructional roles and lifeguarding.
Oxford Biomedica Solutions
Oxford Biomedica Solutions, LLC is the high-performing, full scope Adeno-Associated Virus (AAV) vector Manufacturing and Innovation joint venture of Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), and Homology Medicines, Inc. (Nasdaq: FIXX) (“Homology”). We offer global pharmaceutical and biotechnology clients innovative manufacturing expertise in AAV and lentiviral-based cell and gene therapies. Oxford Biomedica Solutions LLC provides access to Homology’s innovative and proven end-to-end AAV manufacturing capabilities, and customers also benefit from technical synergies brought in by the Group’s know-how in lentiviral vector manufacturing. This collaborative and complementary vector-based approach has the potential to accelerate our collective mission to improve patients’ lives worldwide.